Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Labopin

Showing results (361-370 of 443) with videos related to

Pageof 45
Sort By:
Bone Marrow Transplantation|May 5, 2023
Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMTKlaus Hirschbühl, Myriam Labopin, Emmanuelle Polge, et al.
Leukemia|February 5, 2021
Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMTJordi Esteve, Sebastian Giebel, Myriam Labopin, et al.
Transplantation and Cellular Therapy|August 28, 2022
Impact of Cytogenetic Risk on Outcomes of Non-T-Cell-Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid LeukemiaArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
Haematologica|December 21, 2014
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemiaEolia Brissot, Myriam Labopin, Marielle M Beckers, et al.
Bone Marrow Transplantation|February 5, 2025
The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamideAlexandros Spyridonidis, Myriam Labopin, Bipin P Savani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 6, 2016
Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow TransplantationGiovanna Lucchini, Myriam Labopin, Eric Beohou, et al.
Bone Marrow Transplantation|January 15, 2022
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMTRyszard Swoboda, Myriam Labopin, Sebastian Giebel, et al.
Journal of Hematology & Oncology|July 5, 2020
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donorsEolia Brissot, Myriam Labopin, Ian Moiseev, et al.
Haematologica|December 18, 2012
Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysisAnnalisa Ruggeri, Vanderson Rocha, Emeline Masson, et al.
Cancer|May 25, 2022
Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemiaJustin Loke, Myriam Labopin, Charles Craddock, et al.
Pageof 45

Showing results (361-370 of 443) with videos related to

Sort By:
Pageof 45
Bone Marrow Transplantation|May 5, 2023
Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMTKlaus Hirschbühl, Myriam Labopin, Emmanuelle Polge, et al.
Leukemia|February 5, 2021
Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMTJordi Esteve, Sebastian Giebel, Myriam Labopin, et al.
Transplantation and Cellular Therapy|August 28, 2022
Impact of Cytogenetic Risk on Outcomes of Non-T-Cell-Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid LeukemiaArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
Haematologica|December 21, 2014
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemiaEolia Brissot, Myriam Labopin, Marielle M Beckers, et al.
Bone Marrow Transplantation|February 5, 2025
The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamideAlexandros Spyridonidis, Myriam Labopin, Bipin P Savani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 6, 2016
Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow TransplantationGiovanna Lucchini, Myriam Labopin, Eric Beohou, et al.
Bone Marrow Transplantation|January 15, 2022
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMTRyszard Swoboda, Myriam Labopin, Sebastian Giebel, et al.
Journal of Hematology & Oncology|July 5, 2020
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donorsEolia Brissot, Myriam Labopin, Ian Moiseev, et al.
Haematologica|December 18, 2012
Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysisAnnalisa Ruggeri, Vanderson Rocha, Emeline Masson, et al.
Cancer|May 25, 2022
Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemiaJustin Loke, Myriam Labopin, Charles Craddock, et al.
Pageof 45